An arrangement between Roche Holding Ltd and Novartis AG to increase the sales of an expensive drug in Italy can be considered in breach of EU competition rules, the EU’s top court ruled Tuesday, January 23.
The two Swiss pharmaceutical companies are said to have worked together to discourage doctors from prescribing Roche’s anti-cancer drug Avastin to treat eye diseases, recommending the much more expensive alternative, Lucentis, which is marketed by Novartis.
In 2014, Italy’s competition authority fined the companies each about €90 million (US$110.7 million) over the practice, but the ruling was challenged and Italian appeal judges asked the EU Court of Justice for an opinion on the case.
EU judges said the two companies may be considered guilty of “a restriction of competition,” but said that the final decision on whether to uphold fines against them rests on Italian administrative courts.
Full Content: Courthouse News Service
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Musk’s X Requests Brazil Supreme Court to Resume Service After Shutdown
Sep 26, 2024 by
CPI
Visa Acquires AI Firm Featurespace to Enhance Fraud Prevention
Sep 26, 2024 by
CPI
Visa Gears Up for Legal Fight with DOJ Over Debit Card Monopoly Allegations
Sep 26, 2024 by
CPI
UFC Fighters’ Lawsuit Settlement Resurfaces with $375 Million Offer
Sep 26, 2024 by
CPI
Ex-Amazon Seller Appario Files Lawsuit to Dismiss Antitrust Allegations
Sep 26, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
Francisco Javier Núñez Melgoza
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
Julio Garcia
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
Alejandra Palacios Prieto
The Cost of Making COFECE Disappear
Sep 3, 2024 by
Mateo Fernández